Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease†
Gisela Llebaria BSc
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorJavier Pagonabarraga MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorMercè Martínez-Corral MD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorCarmen García-Sánchez BSc, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorBerta Pascual-Sedano MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorAlexandre Gironell MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorCorresponding Author
Jaime Kulisevsky MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Sant Antoni M. Claret 167, 08025 Barcelona, SpainSearch for more papers by this authorGisela Llebaria BSc
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorJavier Pagonabarraga MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorMercè Martínez-Corral MD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorCarmen García-Sánchez BSc, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorBerta Pascual-Sedano MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorAlexandre Gironell MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Search for more papers by this authorCorresponding Author
Jaime Kulisevsky MD, PhD
Movement Disorders Unit, Neurology Department, Sant Pau Hospital (Sant Pau Institute of Biomedical Research), Autonomous University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Sant Antoni M. Claret 167, 08025 Barcelona, SpainSearch for more papers by this authorPotential conflict of interest: Nothing to report.
Abstract
The development of visual hallucinations (VH) is a frequent complication of Parkinson's disease (PD). Presence of hallucinations is one of the main risk factors associated with dementia, and severity progression of VH mainly contributes to impaired quality of life in PD. The neuropsychological features associated with severity progression of VH are unknown and might help to detect patients at risk of a more severe outcome. We aimed to explore the neuropsychological deficits associated with the different types of VH observed in PD, from minor hallucinations to well-formed VH with loss of insight. Prospective study of 57 PD patients with (n = 29) and without VH (n = 28) matched for age, education, antiparkinsonian medications, and disease duration. Description of VH was assessed by the Hallucinations and Psychosis item of the MDS-UPDRS. Cognition was assessed with the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) and the Mattis Dementia Rating Scale (MDRS). Patients with minor VH did not differ from patients without VH in any cognitive domain. PD patients with major VH and insight retained performed worse on the action verbal fluency task (P < 0.04), and patients with VH and loss of insight showed a greater impairment on the PD-CRS posterior cortical score (P = 0.021) and the clock copying item (P = 0.01). A double dissociation was found in the neuropsychological profile of patients with VH with and without loss of insight. While the presence of major VH with insight retained appeared related to a predominant frontal-striatal impairment, loss of insight was characterized by further impairment of cognitive functions related to posterior cortical areas. A comprehensible continuum pattern of clinical relationships emerged among VH and cognitive functioning in PD. © 2010 Movement Disorder Society.
References
- 1 Williams DR,Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605–610.
- 2 Sanchez-Ramos JR,Ortoll R,Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53: 1265–1268.
- 3 Halliday G,Hely M,Reid W,Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409–415.
- 4 Goetz CG,Leurgans S,Pappert EJ,Raman R,Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001; 57: 2078–2082.
- 5 Mosimann UP,Rowan EN,Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153–160.
- 6 Fenelon G,Mahieux F,Huon R,Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123(Pt 4): 733–745.
- 7 Goetz CG,Tilley BC,Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–2170.
- 8 Factor SA,Feustel PJ,Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60: 1756–1761.
- 9 Goetz CG,Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227–2229.
- 10 Aarsland D,Larsen JP,Tandberg E,Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938–942.
- 11 Goetz CG,Fan W,Leurgans S,Bernard B,Stebbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol 2006; 63: 713–716.
- 12 Holroyd S,Currie L,Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734–738.
- 13 Papapetropoulos S,Argyriou AA,Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005; 252: 1223–1228.
- 14 Ramirez-Ruiz B,Junque C,Marti MJ,Valldeoriola F,Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006; 21: 1483–1487.
- 15 Ramirez-Ruiz B,Junque C,Marti MJ,Valldeoriola F,Tolosa E. Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007; 23: 281–288.
- 16 Santangelo G,Trojano L,Vitale C, et al. A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov Disord 2007; 22: 2418–2425.
- 17 Barnes J,Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry 2008; 79: 190–192.
- 18 Williams-Gray CH,Foltynie T,Brayne CE,Robbins TW,Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787–1798.
- 19 Boecker H,Ceballos-Baumann AO,Volk D,Conrad B,Forstl H,Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007; 64: 984–988.
- 20 Pagonabarraga J,Kulisevsky J,Llebaria G,Garcia-Sanchez C,Pascual-Sedano B,Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23: 998–1005.
- 21 Hughes AJ,Daniel SE,Kilford L,Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
- 22 Grosset K,Needleman F,Macphee G,Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19: 1370–1374.
- 23 Hoehn MM,Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
- 24 Mattis S. Dementia rating scale: professional manual. Florida. Odessa: Odessa; 1988.
- 25 Imamura K,Wada-Isoe K,Kitayama M,Nakashima K. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol Scand 2008; 117: 255–259.
- 26 Nóbrega E,Nieto A,Barroso J,Montón F. Differential impairment in semantic, phonemic, and action fluency performance in Friedreich's ataxia: possible evidence of prefrontal dysfunction. J Int Neuropsychol Soc 2007; 13: 944–952.
- 27 Damasio H,Grabowski T,Tranel D,Ponto L,Hichwa R,Damasio A. Neural correlates of naming actions and of naming spatial relations. Neuroimage 2001; 13: 1053–1064.
- 28 Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236–1238.
- 29 Royall DR,Cordes JA,Polk M. CLOX: an executive clock drawing task. J Neurol Neurosurg Psychiatry 1998; 64: 588–594.
- 30 Papapetropoulos S,McCorquodale DS,Gonzalez J,Jean-Gilles L,Mash DC. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord 2006; 12: 253–256.
- 31 Harding AJ,Broe GA,Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391–403.
- 32 Harding AJ,Stimson E,Henderson JM,Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002; 125: 2431–2445.
- 33 Oishi N,Udaka F,Kameyama M,Sawamoto N,Hashikawa K,Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005; 65: 1708–1715.
- 34 Matsui H,Nishinaka K,Oda M, et al. Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. Mov Disord 2006; 21: 2165–2169.
- 35 Ramirez-Ruiz B,Marti MJ,Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007; 14: 750–756.